Loading
A phase 2 trial of Sonesitatug vedotin, FLOT, FOLFIRI in pancreatic ductal adenocarcinoma, run by AstraZeneca, now recruiting.
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 is a phase 2 interventional study registered as NCT06219941 by AstraZeneca, with 226 participants planned, started 2023-12-13 and due to reach its primary completion in 2026-11-17. Interventions recorded: AZD0901, 5-Fluorouracil, Leucovorin, l-leucovorin, Irinotecan. Conditions listed: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), AstraZeneca.
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Gemcitabine.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Gemcitabine.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan).
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Gemcitabine.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Gemcitabine.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Gemcitabine, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/